{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05115474",
            "orgStudyIdInfo": {
                "id": "MCC-21448"
            },
            "organization": {
                "fullName": "H. Lee Moffitt Cancer Center and Research Institute",
                "class": "OTHER"
            },
            "briefTitle": "Study of Screening Brain MRIs in Stage IV Breast Cancer",
            "officialTitle": "Phase II Study of Screening Brain MRIs in Stage IV Breast Cancer",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "study-of-screening-brain-mris-in-stage-iv-breast-cancer"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2021-12-21",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-01-05",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2026-01",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2021-11-01",
            "studyFirstSubmitQcDate": "2021-11-09",
            "studyFirstPostDateStruct": {
                "date": "2021-11-10",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-16",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-18",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "H. Lee Moffitt Cancer Center and Research Institute",
                "class": "OTHER"
            },
            "collaborators": [
                {
                    "name": "Florida Breast Cancer Foundation",
                    "class": "UNKNOWN"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": false,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The study is a single arm, nonrandomized phase II prospective study, with the goal of investigating the role of screening brain MRIs in neurologically asymptomatic patients with metastatic breast cancer."
        },
        "conditionsModule": {
            "conditions": [
                "Triple Negative Breast Cancer",
                "HER2-positive Breast Cancer",
                "Hormone Receptor-positive Breast Cancer"
            ],
            "keywords": [
                "Stage IV Breast Cancer"
            ]
        },
        "designModule": {
            "studyType": "OBSERVATIONAL",
            "patientRegistry": false,
            "designInfo": {
                "observationalModel": "CASE_ONLY",
                "timePerspective": "PROSPECTIVE"
            },
            "bioSpec": {
                "retention": "SAMPLES_WITH_DNA",
                "description": "Blood samples will be collected to evaluate changes in surrogate biomarkers related to brain metastasis progression. Changes in biomarkers such as cytokines associated with T-cell activation and lymphocyte subpopulations may provide evidence of brain metastasis progression. Furthermore, circulating tumor DNA may identify populations of patients more likely to undergo CNS progression"
            },
            "enrollmentInfo": {
                "count": 100,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Participants with TNBC (triple negative breast cancer)",
                    "description": "Participants will undergo a screening brain MRI. Patients will undergo a second brain MRI at first systemic progression or at 6 months whichever event occurs sooner.",
                    "interventionNames": [
                        "Diagnostic Test: Magnetic Resonance Imaging"
                    ]
                },
                {
                    "label": "Participants with Human Epidermal Growth Factor Receptor 2 (HER2) + Breast Cancer",
                    "description": "Participants will undergo a screening brain MRI. Patients will undergo a second brain MRI at first systemic progression or at 6 months whichever event occurs sooner.",
                    "interventionNames": [
                        "Diagnostic Test: Magnetic Resonance Imaging"
                    ]
                },
                {
                    "label": "Participants with Hormone Receptor (HR) +Breast Cancer",
                    "description": "Participants will undergo a screening brain MRI. Patients will undergo a second brain MRI at first systemic progression or at 6 months whichever event occurs sooner.",
                    "interventionNames": [
                        "Diagnostic Test: Magnetic Resonance Imaging"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DIAGNOSTIC_TEST",
                    "name": "Magnetic Resonance Imaging",
                    "description": "Participants will undergo MRI imaging with and without contrast.",
                    "armGroupLabels": [
                        "Participants with Hormone Receptor (HR) +Breast Cancer",
                        "Participants with Human Epidermal Growth Factor Receptor 2 (HER2) + Breast Cancer",
                        "Participants with TNBC (triple negative breast cancer)"
                    ],
                    "otherNames": [
                        "MRI"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Rate of Brain Metastasis",
                    "description": "Rate of brain metastasis by breast cancer subtype at baseline using MRI images.",
                    "timeFrame": "at Baseline"
                },
                {
                    "measure": "Rate of Brain Metastasis",
                    "description": "Rate of brain metastasis by breast cancer subtype at 6 months or first systemic progression using MRI images.",
                    "timeFrame": "up to 6 months"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Rate of Asymptomatic Leptomeningeal Disease",
                    "description": "Rate of asymptomatic leptomeningeal disease by breast cancer subtype at baseline and at 6 months or first systemic progression, using MRI images.",
                    "timeFrame": "Baseline and at up to 6 months"
                },
                {
                    "measure": "Number of Brain Metastases",
                    "description": "Number of Brain Metastases at Diagnosis by Breast Cancer Subtype, using MRI images.",
                    "timeFrame": "Baseline"
                },
                {
                    "measure": "Overall Survival",
                    "description": "Overall Survival (OS) will be measured from the initial on study date to the recorded date of death.",
                    "timeFrame": "Up to 6 months"
                },
                {
                    "measure": "Number of Participants Requiring Whole Brain Radiation Therapy vs Stereotactic Radiation",
                    "description": "Number of Participants Requiring Whole Brain Radiation Therapy vs Stereotactic Radiation by breast cancer type.",
                    "timeFrame": "Up to 6 months"
                },
                {
                    "measure": "Brain Metastasis Specific Survival",
                    "description": "Brain metastasis specific survival following brain metastasis by breast cancer subtype",
                    "timeFrame": "Up to 6 months"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Histologic diagnosis of breast cancer with documentation of ER/PR/HER2 status\n* Radiographic evidence of stage IV extracranial diease having progressed past first line therapy in HR+/HER2- patients\n* Radiographic evidence of stage IV extracranial disease in TN and HER2+ patients\n* Age \u2265 18\n* Life expectancy \u2265 6 months\n* Eastern Cooperative Oncology Group performance status 0 to 2\n* Patients must be able to understand and the willingness to sign an informed consent for study procedures\n* Stated willingness to comply with all study procedures and availability for the duration of the study\n\nExclusion Criteria:\n\n* Prior diagnosis or treatment of brain metastases or leptomeningeal disease\n* Patients with prior history of non-breast cancer malignancies should have no evidence of disease \u2265 2 years\n* Neurologic symptoms warranting standard screening brain MRI in the judgement of the treating physician at time of enrollment\n* Indications warranting brain MRI for other neurologic conditions at time of study entry\n* Contraindication towards MRI imaging with contrast\n* Chronic kidney disease stage IV or V or end stage renal disease",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ],
            "studyPopulation": "Stage IV breast cancer patients at Moffitt Cancer Center",
            "samplingMethod": "NON_PROBABILITY_SAMPLE"
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Robin Dowell",
                    "role": "CONTACT",
                    "phone": "813-745-0393",
                    "email": "Robin.Dowell@moffitt.org"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Kamran A Ahmed, MD",
                    "affiliation": "Moffitt Cancer Center",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Morton Plant Mease- Baycare",
                    "status": "RECRUITING",
                    "city": "Clearwater",
                    "state": "Florida",
                    "zip": "33756",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Roberto Diaz, MD",
                            "role": "CONTACT",
                            "email": "Roberto.Diaz@baycare.org"
                        },
                        {
                            "name": "Ronica Nanda, MD",
                            "role": "CONTACT",
                            "email": "Ronica.Nanda@baycare.org"
                        },
                        {
                            "name": "Roberto Diaz, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 27.96585,
                        "lon": -82.8001
                    }
                },
                {
                    "facility": "Moffitt Cancer Center",
                    "status": "ACTIVE_NOT_RECRUITING",
                    "city": "Tampa",
                    "state": "Florida",
                    "zip": "33612",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 27.94752,
                        "lon": -82.45843
                    }
                }
            ]
        },
        "referencesModule": {
            "seeAlsoLinks": [
                {
                    "label": "Moffitt Cancer Center Clinical Trials website",
                    "url": "https://www.moffitt.org/clinical-trials-research/clinical-trials/"
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000001943",
                    "term": "Breast Neoplasms"
                },
                {
                    "id": "D000064726",
                    "term": "Triple Negative Breast Neoplasms"
                }
            ],
            "ancestors": [
                {
                    "id": "D000009371",
                    "term": "Neoplasms by Site"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000001941",
                    "term": "Breast Diseases"
                },
                {
                    "id": "D000012871",
                    "term": "Skin Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M5220",
                    "name": "Breast Neoplasms",
                    "asFound": "Breast Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M30373",
                    "name": "Triple Negative Breast Neoplasms",
                    "asFound": "Triple Negative Breast Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M5218",
                    "name": "Breast Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M15674",
                    "name": "Skin Diseases",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC17",
                    "name": "Skin and Connective Tissue Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        },
        "interventionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M9789",
                    "name": "Hormones",
                    "relevance": "LOW"
                },
                {
                    "id": "M11900",
                    "name": "Mitogens",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}